Navigation Links
Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)

REDWOOD CITY, Calif., Sept. 26 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced that results from a Phase 2 trial of glufosfamide plus gemcitabine were presented at the European Cancer Conference (ECCO) annual meeting in Barcelona, Spain.

In the Phase 2 clinical trial of glufosfamide in combination with gemcitabine for the treatment of advanced pancreatic cancer, six-month and one-year survival were 50% (95% CI: 31-67%) and 32% (95% CI: 16 - 49%), respectively. Median progression-free and overall survival were 3.7 and 6.0 months.

"We are encouraged by the results of this Phase 2 study, especially with respect to the one-year survival data which was higher than expected compared to previous studies of either gemcitabine alone or in combination with tarceva," said Barry Selick, Ph.D., chief executive officer of Threshold. "Based on these findings we believe that glufosfamide should have a role in the treatment of pancreatic cancer and, taken together with our Phase 3 results, we will be exploring the best options for its continued development in the treatment of this disease".

In a poster session at ECCO, Dr. Elena (Gabi) Chiorean, Indiana University Cancer Center, Indianapolis, IN, presented the Phase 2 results in a poster entitled, "Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: results of a Phase 2 trial". In the clinical trial, 29 patients were treated, of which 28 patients with pancreatic adenocarcinoma previously untreated with chemotherapy were evaluated for response. Overall, 6 of 28 patients (21%; 95% CI: 8-41%) achieved a partial response including one unconfirmed partial response. Median duration of confirmed responses was 8.4 months. In addition, 11 of 28 patients (39%) experienced stable disease (duration 1.2+ to 12.6+ months). Objective response was assessed radiologically after every two cycles (8 weeks) of therapy. A partial response is characterized as a decrease in size by 30% of the sum of the longest diameters of target lesions, the absence of progression of all non-target lesions and no new lesions.

Grade 3 and 4 neutropenia occurred in 8 (28%) and 15 (52%) patients. Grade 3 and 4 thrombocytopenia occurred in 8 (28%) and 2 (7%) patients. Five patients (18%) had a glufosfamide-related serious adverse event (SAE), which included renal tubular acidosis (RTA) with renal failure (2 patients), RTA alone, vomiting or nausea. Three patients died from an SAE unrelated to glufosfamide. Another patient developed an SAE of renal failure after hypotension associated with pulmonary embolus. The creatinine clearance (CrCL) fell below 60 mL/min in 10 of 27 (37%) patients with CrCL greater than or equal to 60 at baseline.

These data indicate that glufosfamide plus gemcitabine may benefit patients with chemotherapy nave pancreatic adenocarcinoma. Hematologic and renal toxicity may be greater than would be expected with either agent alone although the small numbers preclude definitive conclusions. No unanticipated adverse events based on previous experience with glufosfamide were observed.

The Phase 2 poster is available on the Threshold website at

About Glufosfamide

Glufosfamide combines the active part of ifosfamide, a member of a widely used class of chemotherapy drugs known as "alkylators", with a glucose molecule. Because of its glucose component and a tumor cell's increased need for glucose, glufosfamide may be preferentially transported into tumors compared to most normal tissues. Inside cells, the linkage between glucose and the alkylator is cleaved to release the active drug.

About Pancreatic Cancer

The American Cancer Society estimates that 37,170 patients will be diagnosed with pancreatic cancer in the United States in 2007, and approximately 33,370 patients will die from the disease. Only 15-20% of newly diagnosed patients are eligible for surgery, which is typically followed by radiation and chemotherapy. Patients with inoperable pancreatic cancer are treated with radiation and chemotherapy, or in the case of metastatic disease, chemotherapy alone as the advantages of radiation are reduced.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional information, please visit our website (

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, clinical trial progress and results, potential therapeutic uses and benefits of our product candidates and financial projections. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence, enroll or complete its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). The scientific information discussed in this news release related to our product candidate is preliminary and investigative. The product candidate is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidate. Only the FDA can determine whether the product candidate is safe and effective for the use(s) being investigated. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on August 7, 2007 and is available from the SEC's website ( and on our website ( under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.


Denise T. Powell

Sr. Director, Corporate Communications

Threshold Pharmaceuticals, Inc.


SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Italian ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/25/2015)... , Nov. 26, 2015  The total global healthcare ... 7% over 2015-2016. Latin America has ... , (excluding Japan ), is second ... continues to face increased healthcare expenditure. In 2013-2014, total ... declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. In ...
Breaking Medicine Technology:
(Date:11/26/2015)... VA (PRWEB) , ... November 26, 2015 , ... ... an American Express Travel Representative. As a franchise owner, Somu now offers travelers, ... of cruise, destination wedding packages, private cruise sales, as well as, cabin upgrades ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical ... professionals and offered by healthcare staffing agency Aureus Medical Group . ... of October 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... second medical opinion process, participated in the 61st annual Employee Benefits Conference. The ... and took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference ...
(Date:11/26/2015)... Bangalore, Karnataka (PRWEB) , ... ... ... an innovative online platform for mental health and wellness consultation, has collaborated ... self-empowerment, to holistically address their reader’s queries on topics on mental and ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... more aggressive than those found on mammography, according to a study published online ... additional cancers not seen on mammography may necessitate a change in treatment. , ...
Breaking Medicine News(10 mins):